TapewireFind a company

person · Reporting owner

GARDNER JASON

Disclosed activity across 1 company

Tapewire entity
121909
SEC CIK
0001741286

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813Director · See RemarksNovember 30, 2022December 02, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date November 30, 2022 · Filed December 02, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect292,872 Reported balance After 2022-11-30 transaction · row 1
1 source row

Row 1 · 2022-11-30 · Grant · Acquired 3,000 · Balance 292,872

F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Common StockSEC Table I · non-derivativeIndirectBy J.P. Gardner Irrevocable Trust292,990 Reported balance Holding disclosure · report date 2022-11-30 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 292,990

Common StockSEC Table I · non-derivativeIndirectBy P.S. Gardner Irrevocable Trust359,092 Reported balance Holding disclosure · report date 2022-11-30 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 359,092

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 30, 2022 Filed Dec 2, 2022 21:23 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantCommon Stock 3,000 $0.94 $2,820.00
Disclosure

SEC source: 0000899243-22-037431 · doc4.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,872

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Read SEC document
August 01, 2022 Filed Aug 2, 2022 01:13 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 187,500 $0.00 Strike: $1.57 $0.00
Disclosure

SEC source: 0000899243-22-027271 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2032-07-31

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022.

Read SEC document
May 31, 2022 Filed Jun 6, 2022 20:05 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantCommon Stock 3,000 $0.99 $2,970.00
Disclosure

SEC source: 0000899243-22-021184 · doc4.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,872

F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of December 1, 2021 through May 31, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022.

Read SEC document
May 17, 2022 Filed May 19, 2022 20:23 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 162,500 $0.00 Strike: $1.18 $0.00
Disclosure

SEC source: 0000899243-22-018817 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 162,500 shares

Expires 2032-05-16

F1 · derivative.exercise_date: This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022.

Read SEC document
February 15, 2022 Filed Feb 17, 2022 22:31 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 187,500 $0.00 Strike: $3.19 $0.00
Disclosure

SEC source: 0000899243-22-006830 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 187,500 shares

Expires 2032-02-14

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022.

Read SEC document
September 16, 2021 Filed Sep 20, 2021 21:00 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 14,340 $6.73 $96,508.20
Disclosure

SEC source: 0000899243-21-036599 · doc4.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 286,872

F1 · kind: This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 14, 2021 Filed Sep 16, 2021 23:40 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-036335 · doc4.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 301,212

F1 · kind: On February 11, 2021, the reporting person was granted 100,000 restricted stock units. The restricted stock units vest in two equal installments subject to the achievement of certain performance milestones related to the issuer's business plans. The first performance milestone was achieved, resulting in vesting of 50,000 restricted stock units and the corresponding issuance of 50,000 shares of issuer common stock.

Read SEC document
August 02, 2021 Filed Aug 3, 2021 20:33 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 112,500 $0.00 Strike: $7.11 $0.00
Disclosure

SEC source: 0000899243-21-031272 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2031-08-01

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on August 2, 2021.

Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:46 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 112,500 $0.00 Strike: $10.80 $0.00
Disclosure

SEC source: 0000899243-21-006710 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2031-02-10

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021.

Read SEC document
February 10, 2020 Filed Feb 12, 2020 22:07 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 275,000 $0.00 Strike: $12.28 $0.00
Disclosure

SEC source: 0000899243-20-004301 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2030-02-09

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

Read SEC document
January 10, 2020 Filed Jan 10, 2020 22:01 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 11,200 $15.25 $170,800.00
Disclosure

SEC source: 0001562180-20-000327 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,212

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:01 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 2,800 $15.10 $42,280.00
Disclosure

SEC source: 0001562180-20-000118 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,412

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

Read SEC document
December 23, 2019 Filed Dec 23, 2019 21:41 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 2,897 $15.10 $43,754.55
Disclosure

SEC source: 0001562180-19-006252 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,212

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 20, 2019 Filed Dec 20, 2019 23:22 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 76,711 $15.16 $1,162,616.57
Disclosure

SEC source: 0001562180-19-006221 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,109

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
December 10, 2019 Filed Dec 13, 2019 22:08 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 4,392 $15.10 $66,319.20
Disclosure

SEC source: 0001562180-19-006078 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,820

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

Read SEC document
June 21, 2019 Filed Jun 24, 2019 20:02 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 12,331 $15.11 $186,321.41
Disclosure

SEC source: 0001562180-19-003623 · primarydocument.xml · nonDerivative · entry 2

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,212

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:02 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 SaleCommon Stock 1,669 $15.10 $25,201.90
Disclosure

SEC source: 0001562180-19-003623 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361,543

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

Read SEC document
February 05, 2019 Filed Feb 7, 2019 21:18 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 182,900 $0.00 Strike: $7.13 $0.00
Disclosure

SEC source: 0000899243-19-002869 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,900

Underlying: Common Stock · 182,900 shares

Expires 2029-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries C Preferred Stock · Derivative 21,459 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 8

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By J.P. Gardner Irrevocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 8,304 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries B Preferred Stock · Derivative 19,314 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 7

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By P.S. Gardner Irrevocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 7,474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries B Preferred Stock · Derivative 15,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 6

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By J.P. Gardner Irrevocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 5,804 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries A Preferred Stock · Derivative 36,700 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 5

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By P.S. Gardner Irrevocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 14,203 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries A Preferred Stock · Derivative 30,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · derivative · entry 4

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By J.P. Gardner Irrevocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 11,611 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

F1 · ownership.direct: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 PurchaseCommon Stock 400 $15.00 $6,000.00
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · nonDerivative · entry 3

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,212

F2 · shares: Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionCommon Stock 21,677 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · nonDerivative · entry 2

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By P.S. Gardner Irrevocable Trust

Disclosed balance after: 359,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionCommon Stock 25,719 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018316 · doc4.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By J.P. Gardner Irrevocable Trust

Disclosed balance after: 292,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.